BioTelemetry (BEAT) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BEAT Hot Sheet
Join SI Premium – FREE
BioTelemetry (NASDAQ: BEAT) reported Q3 EPS of $0.16, $0.09 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $81 million versus the consensus estimate of $82.62 million.
For earnings history and earnings-related data on BioTelemetry (BEAT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CoreCivic (CXW) Misses Q3 EPS by 1530c; raises guidance
- Ormat Technologies (ORA) Tops Q3 EPS by 27c; Offers Guidance
- Cognex Corp (CGNX) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
